Higher blood flow rates in anticoagulation-free CRRT improve circuit survival and clinical outcome

Caihong Liu, S T Fan, Liyao Yang, Wei Wei, Yongxiu Huang, Zhiwen Chen, Qian Bu, Fang Wang, Xue Tang, Yingying Yang, Ping Fu, Ling Zhang, Yuliang ZhaoClinical 2025 · DOI

TL;DR

This study demonstrates that increasing blood flow rates (BFR) in anticoagulation-free Continuous Renal Replacement Therapy (CRRT) from 200 ml/min to 250 ml/min significantly improves circuit survival and reduces in-hospital mortality. The enhanced circuit longevity appears to be mediated by a reduction in transmembrane pressure (TMP).

What Problem Does This Paper Address?

Continuous Renal Replacement Therapy (CRRT) is a life-saving treatment for critically ill patients, particularly those at high risk of bleeding who cannot tolerate anticoagulation. However, a major challenge in anticoagulation-free CRRT is the shortened lifespan of the extracorporeal circuit due to clotting. This limits treatment continuity, increases risks, and adds to the workload. While blood flow rate (BFR) is known to influence circuit patency, evidence for its optimal use in anticoagulation-free settings has been sparse and inconsistent, leaving a critical gap in guiding clinical practice for these vulnerable patients.

Methods

This was a retrospective cohort study analyzing data from 128 patients who underwent anticoagulation-free CRRT across seven intensive care units. The primary outcome was circuit lifespan, defined as the time from CRRT initiation to termination due to clotting or other reasons. Patients were stratified into two groups based on their BFR: 200 ml/min (conventional) and 250 ml/min (higher). Statistical analyses included univariate and multivariate Cox proportional hazards regression to identify protective and risk factors for circuit survival. Kaplan-Meier curves were used to compare survival probabilities. Mediation analysis was employed to investigate the role of transmembrane pressure (TMP) in the relationship between BFR and circuit lifespan.

Datasets

The study utilized data from 241 CRRT circuits from 128 patients treated at West China Hospital of Sichuan University between September 2023 and June 2024. This dataset was collected retrospectively from the hospital's electronic medical record system. No new benchmarks were introduced; the study focused on analyzing existing clinical data.

Key Insights and Ideas

  • Higher BFR is a potent protective factor: The most striking finding is that simply increasing the BFR from 200 to 250 ml/min dramatically improves circuit survival in the absence of anticoagulation. This suggests that flow dynamics play a more significant role than previously appreciated in preventing clotting in this specific context.
  • TMP as a mechanistic link: The study provides compelling evidence that the benefit of higher BFR on circuit lifespan is at least partially mediated by a reduction in transmembrane pressure (TMP). This is a crucial insight, as TMP is a known indicator of circuit strain and impending clotting. It suggests that monitoring TMP could be a valuable real-time strategy to predict and prevent circuit failure.
  • Clinical outcomes improve: Beyond circuit survival, the higher BFR group also showed a significant reduction in in-hospital mortality, underscoring the clinical relevance of optimizing this parameter.
  • Specific patient subgroups may benefit more: Subgroup analyses hinted that males and younger patients (<65 years) might experience a greater survival benefit from higher BFR, suggesting potential personalized approaches in the future.

Key Results

  • Circuit Lifespan: The median circuit lifespan was significantly longer in the 250 ml/min group (33.5 hours) compared to the 200 ml/min group (13 hours) (P < .001). This held true for overall, clotted, and the first circuit per patient.
  • 72-hour Circuit Survival: The 250 ml/min group showed significantly improved 72-hour circuit survival (Hazard Ratio [HR] = 0.475, 95% CI: 0.329–0.685, P < .001).
  • Predefined Lifespan Milestones: A higher proportion of circuits in the 250 ml/min group achieved predefined lifespans (e.g., 72 hours: 13.76% vs. 3.79%, P = .005).
  • In-Hospital Mortality: Patients in the 250 ml/min group had significantly lower in-hospital mortality (65.14% vs. 81.06%, P = .005).
  • TMP Mediation: The reduction in TMP accounted for up to 60.32% of the protective effect of higher BFR on circuit lifespan at 12 hours.

Limitations and Future Work

The authors acknowledge several limitations:

  • Retrospective, Single-Center Design: This limits the generalizability of the findings.
  • Potential Selection Bias: Patients with better vascular access and hemodynamic stability might have been preferentially assigned higher BFR, potentially overestimating its benefits.
  • Dynamic BFR Not Monitored: The study focused on fixed BFRs, whereas real-world practice might involve dynamic adjustments.
  • Limited BFR Range: The study only compared 200 ml/min and 250 ml/min, excluding other potential BFRs.
  • Lack of Baseline Disease Severity Adjustment: While some adjustments were made, the absence of full APACHE-II or SOFA scores might limit definitive conclusions on mortality.

Future work should focus on:

  • Larger-scale prospective trials (RCTs): To validate these findings and establish optimal BFR settings.
  • Investigating other BFRs: To determine the ideal range for anticoagulation-free CRRT.
  • Real-time BFR tracking: To better understand the impact of dynamic BFR adjustments.
  • Further elucidating TMP's role: To confirm TMP as a mechanistic intermediary and explore its predictive value.
  • Multifaceted approach: Incorporating vigilant monitoring of hematological parameters, lipid profiles, and optimized operational parameters for comprehensive circuit management.

Summary updated

Abstract

A BFR of 250 ml/min significantly improved circuit survival in anticoagulation-free CRRT compared to 200 ml/min, likely mediated by TMP reduction. Moreover, patients receiving 250 ml/min BFR exhibited lower in-hospital mortality. Our results support adopting a higher BFR to optimize CRRT efficacy in anticoagulation-free settings. Larger-scale prospective trials are needed to validate the findings.
BibTeX
@inproceedings{liu2025higher,
  author = {Caihong Liu and S T Fan and Liyao Yang and Wei Wei and Yongxiu Huang and Zhiwen Chen and Qian Bu and Fang Wang and Xue Tang and Yingying Yang and Ping Fu and Ling Zhang and Yuliang Zhao},
  title = {{Higher blood flow rates in anticoagulation-free CRRT improve circuit survival and clinical outcome}},
  booktitle = {Clinical},
  year = {2025},
  doi = {10.1093/ckj/sfaf360},
}
Figure